Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
149
-
Total 13F shares, excl. options
-
30.8M
-
Shares change
-
+405K
-
Total reported value, excl. options
-
$801M
-
Value change
-
-$1.3M
-
Put/Call ratio
-
1.53
-
Number of buys
-
63
-
Number of sells
-
-70
-
Price
-
$26.00
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q4 2020
194 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2020.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 149 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.8M shares
of 207M outstanding shares and own 14.85% of the company stock.
Largest 10 shareholders include Bellevue Group AG (5.14M shares), WASATCH ADVISORS INC (4M shares), Meditor Group Ltd (2.68M shares), STATE STREET CORP (2.52M shares), VANGUARD GROUP INC (2.37M shares), BlackRock Inc. (2.06M shares), PLATINUM INVESTMENT MANAGEMENT LTD (1.56M shares), MARSHALL WACE, LLP (1.38M shares), Rhenman & Partners Asset Management AB (592K shares), and BOXER CAPITAL, LLC (500K shares).
This table shows the top 149 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.